Sunitinib Malate (SU011248)

DRUG4 trials

Conditions

Carcinoma, Renal CellFibrosarcomaGastrointestinal Neoplasms, Gastrointestinal Stromal TumorsGastrointestinal Stromal TumorsLeiomyosarcomaLiposarcomaMalignant Fibrous Histiocytoma

Phase 1

A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)

CompletedNCT00457743

PfizerGastrointestinal Stromal Tumors

Start: 2005-01-31End: 2008-08-31Updated: 2009-11-13

Phase 2

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

CompletedNCT00400569

H. Lee Moffitt Cancer Center and Research InstituteFibrosarcoma, Leiomyosarcoma, Liposarcoma +1

Start: 2006-11-30End: 2011-12-31Updated: 2012-08-28

Phase 4

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

CompletedNCT00706706

PfizerCarcinoma, Renal Cell

Start: 2008-07-31End: 2011-08-31Updated: 2013-01-18

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

CompletedNCT00793871

PfizerGastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Start: 2008-11-30End: 2014-10-31Updated: 2015-11-20

Related Papers

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Nature Medicine2024-01-0546 citations

Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors

Oncology and Therapy2017-09-254 citations

Sunitinib in Chinese patients with advanced gastrointestinal stromal tumor (GIST).

Journal of Clinical Oncology2015-05-203 citations